The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET

類似資料

• ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib
  著者:: Li, Yiting, 等
  出版事項: (2019)
• Overcoming acquired resistance of EGFR-mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589)
  著者:: Zang, Hongjing, 等
  出版事項: (2020)
• Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib
  著者:: Gu, Jiajia, 等
  出版事項: (2020)
• Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
  著者:: Liu, Yutao, 等
  出版事項: (2018)
• Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
  著者:: Zang, Hongjing, 等
  出版事項: (2020)